New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 18, 2012
16:24 EDTORCL, SWHC, RGR, ARB, NLSN, HEB, GTATOn The Fly: Closing Wrap
Stocks on Wall Street were higher, with the buying spurred on by optimism surrounding the fiscal cliff negotiations. After surging higher during the first half of the trading session, the averages moved in a narrow range through the afternoon, though held onto gains and closed right near their highs... ECONOMIC EVENTS: In the U.S., the National Association of Home Builders index of builder confidence increased to 47, as was forecast. Also, the current-account deficit in the U.S. narrowed in the third quarter to $107.5B from a $118.1B shortfall in the prior quarter. Economists expected the deficit would narrow to about $103B... COMPANY NEWS: After the bell, Oracle (ORCL) reported earnings and revenues that beat Street expectations. Shares, which had been up 1.67% during the trading session, moved up another 1.5% in after hours trading following the report... Gunmakers Smith & Wesson (SWHC) and Sturm, Ruger (RGR) continued their recent weakness as private equity firm Cerberus Capital Management's decision to put gunmaker Freedom Group up for sale added new pressure on those stocks. Shares of Smith & Wesson lost 86c, or 9.99%, to close at $7.79, while shares of Sturm, Ruger fell $3.40, or 7.73%, to close at $40.60... MAJOR MOVERS: Among the notable gainers was Arbitron (ARB), up $8.99, or 23.63%, to $47.03 after agreeing to be bought by Nielsen (NLSN) for $48 per share in cash. Shares of acquirer Nielsen also gained $1.30, or 4.39%, to $30.92. Among the noteworthy losers was GT Advanced Technologies (GTAT), which was downgraded at Raymond James and Stifel Nicolaus and saw shares fall 39c, or 11.27%, to $3.07 after issuing guidance well below consensus. Also lower was Hemispherex Biopharma (HEB), down 27.6c, or 42.86%, to 36.8c, after the FDA posted documents in advance of a review of the company's Ampligen drug, noting that the agency had concerns with the drug's efficacy and safety data... INDICES: The Dow was up 115.57, or 0.87%, to 13,350.96; the Nasdaq was up 43.93, or 1.46%, to 3,054.53; and the S&P 500 was up 16.43, or 1.15%, to 1,446.79.
News For ORCL;SWHC;RGR;ARB;NLSN;HEB;GTAT From The Last 14 Days
Check below for free stories on ORCL;SWHC;RGR;ARB;NLSN;HEB;GTAT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 22, 2014
09:03 EDTNLSNNielsen, Pointlogic announce alliance
Subscribe for More Information
08:41 EDTHEBHemispherx achieves high ranking in sensitivity testing against MERS/SARS
Subscribe for More Information
July 17, 2014
12:44 EDTNLSNNielsen downgraded to Hold from Buy at Pivotal Research
Subscribe for More Information
July 16, 2014
08:08 EDTORCLOracle Social Cloud announces LinkedIn support for SRM platform
Subscribe for More Information
07:24 EDTNLSNSiemer & Associates to hold a summit
Subscribe for More Information
July 15, 2014
06:13 EDTNLSNFacebook, Nielsen team up to track TV habits, LA Times reports
Subscribe for More Information
July 14, 2014
12:49 EDTORCLOracle hosts an educational webcast
Subscribe for More Information
10:18 EDTGTATGT Advanced retreats after downgrade citing production concerns
Subscribe for More Information
08:39 EDTHEBHemispherx, Bioclones announce strategic alliance
Hemispherx Biopharma announced a strategic alliance to develop multiple projects with Bioclones. Bioclones and Hemispherx concluded strategic discussions in Johannesburg with three principal goals; initiating studies utilizing Ampligen as a potential adjuvant enhancement of Bioclones' therapeutic cancer vaccine, currently in clinical trials in Cape Town, including pre-clinical studies followed, potentially, by a Phase 1 clinical trial; seeking South African Medicine's Control Council approval to conduct trials using Alferon to eradicate the HIV virus in patients highly responsive to anti-retroviral therapy; and initiating a joint effort to obtain commercial registration of both Ampligen and Alferon in the South African markets. The first clinical program builds on the Bioclones patented therapeutic human dendritic cell, or DC, cancer vaccination approach. This invention provides a method of producing mature DCs in vitro, which comprises the step of culturing the immature DCs, thereafter exposing said cells to tumor antigens before administration to patients. The team has successfully obtained the necessary Ethics approval to use Ampligen as an adjuvant in the Bioclones pre-clinical cancer immunotherapy program utilizing patient derived samples. Pre-clinical studies will be directed towards the potential treatment of breast cancer in particular, followed by prostate cancer. These studies are part of the effort to develop patient-specific DC immunotherapy vaccines against breast cancer and prostate cancer, which elicit an immune response that will target and kill cancer cells. Human DCs matured with Ampligen and transfected with autologous tumor-specific mRNA are designed to elicit a potent and autologous tumoricidal antigen-specific cytotoxic response to the cancer.
07:41 EDTGTAT, GTATGT Advanced 's 2014 guidance at risk, says CLSA
Subscribe for More Information
July 10, 2014
16:15 EDTORCLKEYW, Oracle collaborate on advanced security solutions
Subscribe for More Information
07:20 EDTORCLIridium completes implementation of Oracle's management and billing solution
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use